undamentalytics Newsletter

Angiodynamics Inc insider trading

Every open-market purchase and sale by Angiodynamics Inc's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.
Angiodynamics Inc insider open-market trades
DateInsiderTrade SharesPriceValue 1M after 3M after 6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Angiodynamics Inc’s insiders pay?

From February 8, 2010 to October 30, 2026, 20 insiders reported 32 open-market purchases and 28 sales not made under a pre-set plan in Angiodynamics Inc. Twelve months after each purchase was reported, the shares were −8.6% against the S&P 500 on average (median −21.6%), over 32 purchases with a full year of prices; 34% beat the index. After sales, the shares moved −23.2% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on February 9, 2010 into $15,851 by November 2, 2026, +2.8% a year. It held shares 70% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $67,427 (+12.1% a year), and held throughout $94,773 (+14.4%).

$0$50.0k$100k 201020122014201620182020202220242026 $94.8k$67.4k$15.9k
Copying Angiodynamics Inc's insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Angiodynamics Inc's insiders from February 9, 2010, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 70% of the time.
Angiodynamics Inc: each insider's record
InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
Bucci Vincent Director 8 −17.1% (8) 25% 0 — October 21, 2013
Clemmer James C President and CEO 8 +13.8% (8) 50% 0 — October 9, 2025
Helsel Dave SVP Global Operations and R&D 0 — — 5 −52.4% (5) February 1, 2023
Devivo Joseph President and CEO 4 −28.2% (4) 0% 0 — July 18, 2012
Gould Kevin J Director 3 −6.9% (3) 33% 1 −67.8% (1) July 18, 2019
Greiner Charles R VP - Global Franchise 0 — — 4 −4.2% (4) May 9, 2016
Richard Stark SVP, GM - Oncology 0 — — 4 −14.0% (4) November 17, 2017
Trowbridge Stephen A EVP and CFO 2 −50.9% (2) 0% 2 +8.6% (1) October 30, 2026
Burgstahler David F Director 0 — — 3 −3.3% (3) April 14, 2017
Johnson Wesley Director 1 −24.3% (1) 0% 2 −26.1% (2) April 13, 2022
Donnelly Howard W Director 1 +11.0% (1) 100% 1 −10.6% (1) July 21, 2017
Kapusta Matthew C SVP, Business Development 2 −14.7% (2) 50% 0 — April 16, 2014
Nighan Warren Jr SVP Quality and Regulatory 0 — — 2 −26.6% (1) July 31, 2026
Campbell Chad Thomas SVP/GM, Vascular Access 0 — — 1 −24.3% (1) October 6, 2021
Centea Scott Sr. VP/GM, Global VIT 0 — — 1 −33.3% (1) October 18, 2021
Gold Jeffrey Director 1 +17.1% (1) 100% 0 — November 13, 2012
Greiner Michael EVP and CFO 0 — — 1 −43.4% (1) November 8, 2018
Meteny Dennis S Director 1 +26.4% (1) 100% 0 — March 12, 2013
Navilyst Medical Co-Invest, LLC 10% owner 0 — — 1 −9.4% (1) August 5, 2016
Weiss Lawrence T SVP, Chief Legal Officer 1 −13.8% (1) 0% 0 — October 22, 2025

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Angiodynamics Inc

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Angiodynamics Inc in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 6 buying crowds with six months of prices, it averaged −14.6% against the index. After 1 selling crowd, −17.0%. One company's history is too short to judge by; the test across every company is the better guide.

MonthCrowd3 months on, vs S&P 5006 months12 months
October 31, 20252 buying−12.9%−15.6%not yet
October 31, 20222 buying−12.0%−45.0%−66.8%
January 31, 20222 buying+5.2%+16.2%−31.0%
October 29, 20213 selling−22.7%−17.0%−36.1%
July 31, 20172 buying+0.8%−9.2%+14.0%
January 31, 20132 buying−24.4%−15.7%+9.0%
February 29, 20122 buying−4.9%−18.5%−17.7%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Angiodynamics Inc · Funds · Politicians